[email protected]
CDI - Contrive Datum Insights
Pharmaceuticals & Biotech

Antibody Discovery MarketSize, Share & Industry Analysis, 2026-2034By TechnologyBy Antibody FormatBy OfferingBy Workflow StageBy Therapeutic AreaBy Antibody OriginBy Target ClassBy End UserBy Business Model

Full title & scope — all 9 axes with their segments

Antibody Discovery Market Size, Share & Industry Analysis, By Technology (Phage Display, Hybridoma Technology, Transgenic Animal Platforms, Single B-Cell Technologies, Yeast Display, Mammalian and Cell-Free Display, AI and Computational Discovery), By Antibody Format (Full-Length Monoclonal Antibodies, Bispecific and Multispecific Antibodies, Antibody Fragments, Single-Domain Antibodies, Antibody-Drug Conjugate Antibodies, Polyclonal Antibodies), By Offering (Discovery Services, Libraries and Reagents, Software and Informatics, Instruments and Platforms), By Workflow Stage (Target Identification and Validation, Hit Identification, Lead Optimization, Preclinical Characterization, Developability Assessment), By Therapeutic Area (Oncology, Autoimmune and Inflammatory Diseases, Infectious Diseases, Neurological Disorders, Metabolic and Cardiovascular Diseases, Other Therapeutic Areas), By Antibody Origin (Fully Human, Humanized, Chimeric, Murine), By Target Class (Immune Checkpoints, Cell-Surface Tumor Antigens, Cytokines and Cytokine Receptors, GPCRs and Ion Channels, Viral and Bacterial Antigens), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes, Government and Public Research Bodies), By Business Model (Fee-for-Service, Platform Licensing, Collaborative Co-Development, In-House Discovery), and Regional Forecast, 2026-2034

Last Updated: Nov 16, 2026Format: PDFReport ID: CDI-248896
Segmentation

Segment definitions and share of revenue by product, animal, end user and region.

Segmented by
Technology
Antibody Format
Offering
Workflow Stage
Therapeutic Area
Antibody Origin
Target Class
End User
Business Model
Structure

Segmentation Analysis

9 axes

By Technology

7
  • 01Phage Display
  • 02Hybridoma Technology
  • 03Transgenic Animal Platforms
  • 04Single B-Cell Technologies
  • 05Yeast Display
  • 06Mammalian and Cell-Free Display
  • 07AI and Computational Discovery

By Antibody Format

6
  • 01Full-Length Monoclonal Antibodies
  • 02Bispecific and Multispecific Antibodies
  • 03Antibody Fragments
  • 04Single-Domain Antibodies
  • 05Antibody-Drug Conjugate Antibodies
  • 06Polyclonal Antibodies

By Offering

4
  • 01Discovery Services
  • 02Libraries and Reagents
  • 03Software and Informatics
  • 04Instruments and Platforms

By Workflow Stage

5
  • 01Target Identification and Validation
  • 02Hit Identification
  • 03Lead Optimization
  • 04Preclinical Characterization
  • 05Developability Assessment

By Therapeutic Area

6
  • 01Oncology
  • 02Autoimmune and Inflammatory Diseases
  • 03Infectious Diseases
  • 04Neurological Disorders
  • 05Metabolic and Cardiovascular Diseases
  • 06Other Therapeutic Areas

By Antibody Origin

4
  • 01Fully Human
  • 02Humanized
  • 03Chimeric
  • 04Murine

By Target Class

5
  • 01Immune Checkpoints
  • 02Cell-Surface Tumor Antigens
  • 03Cytokines and Cytokine Receptors
  • 04GPCRs and Ion Channels
  • 05Viral and Bacterial Antigens

By End User

4
  • 01Pharmaceutical and Biotechnology Companies
  • 02Contract Research Organizations
  • 03Academic and Research Institutes
  • 04Government and Public Research Bodies

By Business Model

4
  • 01Fee-for-Service
  • 02Platform Licensing
  • 03Collaborative Co-Development
  • 04In-House Discovery

Segment categories shown for scope reference. See the Summary tab for revenue share by Technology. Full segment-by-segment detail across every axis is available in the sample and full report.

Scope

Questions This Report Answers

6 questions
01

What is the market size and growth rate, globally and by region?

02

How is the market segmented, and which segments lead?

03

Which regions and countries are covered, and how do they compare?

04

What are the key drivers, restraints, opportunities and challenges?

05

Who are the leading companies operating in this market?

06

What trends are expected to shape the market through the forecast period?

Questions

Frequently Asked Questions

01What is the Antibody Discovery Market projected to reach?

USD 23.2 USD Billion by 2034, CAGR 11.23%

02What years does this report cover?

Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.

03Which regions are covered?

North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

04Which region accounted for the largest market share?

North America leads with 43.5% of global revenue through 2034.

05Which segment leads the market?

Phage Display is the largest line by technology, at 23.98% of revenue in 2025.

06Who are the key companies profiled?

Adimab, LLC, AbCellera Biologics Inc., OmniAb, Inc., Charles River Laboratories International, Inc., WuXi Biologics (Cayman) Inc., GenScript Biotech Corporation, Evotec SE, Twist Bioscience Corporation, Absci Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Bio-Techne Corporation, Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Harbour BioMed, Creative Biolabs, Sino Biological Inc., Abzena Ltd., Bruker Corporation, Lonza Group Ltd, XOMA Royalty Corporation, BigHat Biosciences, Inc., Crescendo Biologics Ltd., Absolute Antibody Ltd., Sartorius AG, Bio-Rad Laboratories, Inc., Aragen Life Sciences Ltd.. Full profiles are part of the paid report.

07Can the segmentation be customized?

Yes. Custom data cuts by geography, segment, or competitor set are available on request.

425+
Dedicated research analysts
1,200+
Reports published
Why CDI

Why choose CDI

Data triangulated across primary and secondary sources
Complimentary analyst call included with every purchase
Custom data cuts and post-purchase support available

Need this report shaped around your question?

The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.

Most licences include 30–60 hours of customization at no extra cost. See what each licence includes

Request customization

Additional Companies

Add competitors, suppliers or the peer set you benchmark against to the companies already covered.

Deeper Competitive View

Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.

Extra Segment Splits

Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.

Application Focus

Narrow the analysis to the specific use cases and end users your team actually sells into.

Different Time Frame

Move the base year, or widen the historical and forecast windows the study is built on.

Country-Level Detail

Go below region level into the individual countries that matter to you, rather than the standard geography split.